ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Shares Pass Above 50 Day Moving Average – Time to Sell?

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) crossed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $88.19 and traded as high as $102.28. ProShares Ultra Nasdaq Biotechnology shares last traded at $99.86, with a volume of 16,137 shares.

ProShares Ultra Nasdaq Biotechnology Stock Performance

The firm has a market capitalization of $83.88 million, a P/E ratio of 20.68 and a beta of 1.19. The business has a fifty day moving average of $88.19 and a 200-day moving average of $84.84.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Citadel Advisors LLC acquired a new position in shares of ProShares Ultra Nasdaq Biotechnology during the third quarter valued at $307,000. Franklin Resources Inc. acquired a new stake in ProShares Ultra Nasdaq Biotechnology in the second quarter worth about $32,000. Finally, Kaizen Financial Strategies lifted its holdings in ProShares Ultra Nasdaq Biotechnology by 4.7% in the first quarter. Kaizen Financial Strategies now owns 5,565 shares of the exchange traded fund’s stock worth $483,000 after purchasing an additional 250 shares during the period.

ProShares Ultra Nasdaq Biotechnology Company Profile

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day.